exRNAdisease

General Information

Database ID:

exR0087840

RNA Name:

hsa-miR-18a-5p

RNA Type:

miRNA

Chromosome:

chr13

Starnd:

Coordinate:

Start Site(bp):

91350756

End Site(bp):

91350778

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
PATZ1	chr22	31325804	31346346	-
TUBA4A	chr2	219249710	219278170	-
SURF4	chr9	133361450	133376166	-
DDX5	chr17	64498254	64508199	-
SND1	chr7	127652194	128092609	+
HIF1AN	chr10	100529072	100559998	+
SIK2	chr11	111602449	111730855	+
FKBP1A	chr20	1368978	1393172	-
USP10	chr16	84699978	84779922	+
PARL	chr3	183829271	183884933	-
ASF1B	chr19	14119512	14136613	-
PRPF38B	chr1	108692310	108702928	+
ADAT2	chr6	143422832	143450695	-
ZNF12	chr7	6688433	6706947	-
DNAJC9	chr10	73183362	73247255	-
AC131160.1	chr3	183815568	183884889	-
ACSS2	chr20	34872146	34927962	+
MRPS18A	chr6	43671303	43687791	-
XRCC6	chr22	41621119	41664048	+
ROMO1	chr20	35699272	35700984	+
PEX5	chr12	7188685	7218574	+
NDUFV2	chr18	9102630	9134345	+
UBE2Z	chr17	48908407	48929056	+
NOP58	chr2	202265736	202303661	+
RNF4	chr4	2462220	2625320	+
CHD1	chr5	98853985	98928957	-
ATP2B1	chr12	89588049	89709300	-
SLC41A1	chr1	205789094	205813748	-
NCDN	chr1	35557473	35567274	+
HMGCS1	chr5	43287470	43313512	-

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0000712	chr16	68208276	68225678	+
hsa_circ_0001186	chr21	35475133	35475818	+
hsa_circ_0001247	chr22	46125304	46136418	+
hsa_circ_0000921	chr19	30476129	30477324	+
hsa_circ_0000943	chr19	47421744	47440665	+

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC073896.4	chr12	56162359	56190284	-
AC093010.3	chr3	114314501	114329714	-
AC145207.5	chr17	81878425	81881106	-
AL162171.3	chr14	88589231	88592408	+
AP005263.1	chr18	9102736	9254346	+
CASC2	chr10	118046279	118210158	+
GAS5	chr1	173858559	173868882	-
NEAT1	chr11	65422774	65445540	+
SNHG1	chr11	62851984	62855953	-
SNHG15	chr7	44983023	44986961	-
XIST	chrX	73820649	73852723	-

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.